Alumis soars as TYK2 drug hits mark in psoriasis trials
Alumis soars as TYK2 drug hits mark in psoriasis trials
Alumis soars as TYK2 drug hits mark in psoriasis trials
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.